High-throughput cell-based assays for the preclinical development of DsbA inhibitors as antivirulence therapeutics.
A. D. Verderosa, R. Dhouib, Y. Hong, B. Heras, M. Totsika
This paper establishes a high-throughput cell-based assay pipeline for evaluating DsbA inhibitors as antivirulence therapeutics using Escherichia coli and UPEC.
bioRxiv · Mar 3, 2020Microbiology